Skip to content

Study · Randomized controlled trial · n = 144 · 2025

2 results

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

Gasiorek A, Heydorn A, Gabery S, Hjerpsted JB, Kirkeby K, Kruse T, Petersen SB, Toubro S, Vegge A, Key C

Lancet (London, England)20 Jun 2025Cited by 33 (Europe PMC)

PMID40550229 (opens in a new tab)DOI10.1016/s0140-6736(25)01176-6 (opens in a new tab)PepBankPUB-40550229
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In participants with overweight or obesity, amycretin plasma concentrations were consistent with dose proportionality across treatment groups.

    In plain wordsIn participants with overweight or obesity, amycretin blood concentrations increased in proportion to dose.

    Peptide
    Amycretin
    Outcome
    IncreaseDose proportionality
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Amycretin plasma concentrations were consistent with dose proportionality across all treatment groups.
    1 context sentence
    Summary · context
    In this phase 1, first-in-human, randomised, double-blind, placebo-controlled multipart study, participants were recruited at a single clinical research unit in San Antonio (TX, USA).
  2. 02HumanRandomized controlled trialSafety outcome

    In the oral amycretin trial, no deaths were reported.

    In plain wordsIn the oral amycretin trial, no participants died.

    Peptide
    Amycretin
    Outcome
    Not applicableDeaths
    Study

    n = 144

    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    No deaths were reported.
    1 context sentence
    Summary · context
    In this phase 1, first-in-human, randomised, double-blind, placebo-controlled multipart study, participants were recruited at a single clinical research unit in San Antonio (TX, USA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT05369390

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

Novo Nordisk A/Sn = 14411 May 2022 to 9 Jan 2024

Obesity

Trial pageClinicalTrials.govUpdated 15 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.